The 2024.V4 of the NCCN Clinical Practice Guidelines for Colon Cancer provides important updates on pathological testing of systemic therapy for colon cancer, dose of chemoradiotherapy, and treatment and management of metastatic colon cancer. Firstly, the guidelines emphasize the importance of genomic testing in the systemic treatment of metastatic colon cancer. Secondly, the dose of chemoradiotherapy and targeted therapeutic targets of locally advanced colon cancer were modified. Finally, the new drug repitinib for the second-line treatment of metastatic colon cancer provides a new option for patients with positive neurotrophic tyrosine receptor kinase (NTRK) gene fusion. In terms of patient management, the importance of general practice to patients' quality of life and psychological support was emphasized. Through the interpretation of the above content, this paper is expected to provide references for the diagnosis, treatment and prognosis of colon cancer, ensure that patients receive timely specialized treatment, and provide references for the precision treatment of colon cancer.

2024年V4版《NCCN结肠癌临床实践指南》对结肠癌全身疗法病理检测、放化疗剂量、转移性结肠癌治疗和管理进行了重要更新。首先，指南强调了基因组检测在转移性结肠癌全身治疗中的重要性。其次，修改了局部进展期结肠癌放化疗剂量与靶向治疗靶点。最后，新增转移性结肠癌二线治疗新药瑞普替尼，为神经营养酪氨酸受体激酶（NTRK）基因融合阳性患者提供新的选择。在患者管理方面，强调了全科医学对患者生活质量和心理支持的重要性。本文通过对以上内容进行解读，期待为结肠癌诊断、治疗及预后提供参考，确保患者及时得到专科治疗，为结肠癌精准化治疗提供借鉴。